Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg Recruitment through CCL22 Production by Tumor Cells
Published version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
In breast carcinomas, patient survival seems to be negatively affected by the recruitment of regulatory T cells (Treg) within lymphoid aggregates by CCL22. However, the mechanisms underpinning this process, which may be of broader significance in solid tumors, have yet to be described. In this study, we determined how CCL22 production is controlled in tumor cells. In human breast carcinoma cell lines, CCL22 was secreted at low basal levels that were strongly increased in response to inflammatory signals [TNF-α, IFN-γ, and interleukin (IL)-1β], contrasting with CCL17. Primary breast tumors and CD45+ infiltrating immune cells appeared to cooperate in driving CCL22 secretion, as shown clearly in cocultures of breast tumor cell lines and peripheral blood mononuclear cells (PBMC) or their supernatants. We determined that monocyte-derived IL-1β and TNF-α are key players as monocyte depletion or neutralization of these cytokines attenuated secretion of CCL22. However, when purified monocytes were used, exogenous human IFN-γ was also required to generate this response suggesting a role for IFN-γ–producing cells within PBMCs. In this setting, we found that human IFN-γ could be replaced by the addition of (i) IL-2 or K562-activated natural killer (NK) cells or (ii) resting NK cells in the presence of anti-MHC class I antibody. Taken together, our results show a dialogue between NK and tumor cells leading to IFN-γ secretion, which in turn associates with monocyte-derived IL-1β and TNF-α to drive production of CCL22 by tumor cells and subsequent recruitment of Treg. As one validation of this conclusion in primary breast tumors, we showed that NK cells and macrophages tend to colocalize within tumors. In summary, our findings suggest that at early times during tumorigenesis, the detection of tumor cells by innate effectors (monocytes and NK cells) imposes a selection for CCL22 secretion that recruits Treg to evade this early antitumor immune response. Cancer Res; 71(19); 6143–52. ©2011 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In breast cancer, the CCR4‐CCL22 signaling axis was reported to induce increased migration of regulatory T cells in TME, which in turn leads to the exclusion of effector T cells in the TME [356, 357].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [357]
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Bonecchi, R., Bianchi, G., Bordignon, P. P., D'Ambrosio, D., Lang, R., Borsatti, A., Sozzani, S., Allavena, P., Gray, P. A., Mantovani, A., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.1.129 · Cited by 2,014
Gao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,110
The Role of Chemokine Receptors in Primary, Effector, and Memory Immune Responses
Sallusto, F., Mackay, C. R., & Lanzavecchia, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.593 · Cited by 1,041
Regulation of human NK-cell cytokine and chemokine production by target cell recognition
Fauriat, C., Long, E. O., Ljunggren, H.-G., & Bryceson, Y. T. (2010) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 891
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
Self-citationPrognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers
Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay, N. E. H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1886 · Cited by 598
Regulatory Lymphocytes and Intestinal Inflammation
Izcue, A., Coombes, J. L., & Powrie, F. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132657 · Cited by 507
Godiska, R., Chantry, D., Raport, C. J., Sozzani, S., Allavena, P., Leviten, D., Mantovani, A., & Gray, P. W. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.9.1595 · Cited by 476
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
Regulatory T cells in cancer immunotherapy
Nishikawa, H., & Sakaguchi, S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.12.005 · Cited by 705
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695
“This has been demonstrated experimentally for CCR4, whose ligands CCL17 and/or CCL22 can be expressed by tumor cells or tumor associated myeloid cells (Curiel et al., 2004; Faget et al., 2011; Sugiyama et al., 2013).”
Key chemokines direct migration of immune cells in solid tumors
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583
Metadata
- Authors
- Faget, J., Biota, C., Bachelot, T., Gobert, M., Treilleux, I., Goutagny, N., Durand, I., Léon-Goddard, S., Blay, J. Y., Caux, C., & Ménétrier-Caux, C.
- Affiliations
- Lyon 1 Université (FR)
- Authors' Affiliations: 1Centre Léon Bérard; 2Université Lyon 1; and 3Institut National de la Sant6 et de la Recherche Mddicale U1052, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France
- Venue
- Cancer Research
- Published
- 2011-09-29
- Volume
- 71
- Issue
- 19
- Pages
- 6143-6152
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2128334384
- Cited by
- 129
- References
- 49
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 5 · 2023: 8 · 2022: 12 · 2021: 9 · 2020: 7 · 2019: 8 · 2018: 4 · 2017: 5 · 2016: 13 · 2015: 10 · 2014: 9 · 2013: 9 · 2012: 13
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CCL22, regulatory T cells, breast cancer, tumor immune evasion, natural killer cells, monocytes, IL-1β, TNF-α, interferon-gamma, CCL17, tumor-infiltrating lymphocytes, macrophages, innate immune surveillance, tumor microenvironment, cytokine signaling
- MeSH terms
- Breast Neoplasms, Cell Communication, Cytotoxicity, Immunologic, Female, Humans, Immunity, Innate, Interferon-gamma, Killer Cells, Natural, Leukocytes, Mononuclear, Lymphocyte Activation, Tumor Necrosis Factor-alpha, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Interleukin-1beta, Chemokine CCL22
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg Recruitment through CCL22 Production by Tumor Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-0573
- The paper
- Faget, J., Biota, C., Bachelot, T., Gobert, M., Treilleux, I., Goutagny, N., Durand, I., Léon-Goddard, S., Blay, J. Y., Caux, C., & Ménétrier-Caux, C. (2011). Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg Recruitment through CCL22 Production by Tumor Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-0573
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.